Atomoxetine
Strattera (atomoxetine) is a small molecule pharmaceutical. Atomoxetine was first approved as Strattera on 2002-11-26. It is used to treat attention deficit disorder with hyperactivity in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent serotonin transporter and sodium-dependent dopamine transporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Strattera (generic drugs available since 2010-09-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atomoxetine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STRATTERA | Eli Lilly | N-021411 RX | 2002-11-26 | 7 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atomoxetine | ANDA | 2023-03-09 |
| strattera | New Drug Application | 2020-02-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulpitis | D011671 | EFO_1001139 | K04.0 | 1 | — | 1 | 3 | 4 | 9 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 2 | — | 2 | 1 | 5 |
| Local anesthesia | D000772 | — | — | 1 | 3 | 1 | 5 | ||
| Tooth extraction | D014081 | — | — | — | 1 | 1 | 2 | ||
| Dental anesthesia | D000766 | — | — | — | 1 | 1 | 2 | ||
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
| Aortic valve disease | D000082862 | — | — | — | 1 | — | 1 | ||
| Atrial heart septal defects | D006344 | EFO_1000825 | Q21.1 | — | — | — | 1 | — | 1 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | 1 | — | 1 |
| Postoperative pain | D010149 | G89.18 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | — | 3 | — | — | — | 3 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | 3 | — | — | — | 3 |
| Dental enamel hypoplasia | D003744 | EFO_1001304 | 2 | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
| Toothache | D014098 | K08.89 | — | — | — | — | 1 | 1 | |
| Operative dentistry | D003814 | — | — | — | — | 1 | 1 | ||
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | — | 1 | 1 |
| Procedural pain | D000073818 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ATOMOXETINE |
| INN | atomoxetine |
| Description | Atomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. It has a role as an adrenergic uptake inhibitor, an antidepressant, a xenobiotic and an environmental contaminant. It is an aromatic ether, a secondary amino compound and a member of toluenes. |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNCC[C@@H](Oc1ccccc1C)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 83015-26-3 |
| RxCUI | 38400 |
| ChEMBL ID | CHEMBL641 |
| ChEBI ID | 127342 |
| PubChem CID | 54841 |
| DrugBank | DB00289 |
| UNII ID | ASW034S0B8 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
SLC6A4
SLC6A4
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Variants
Clinical Variant
No data
Financial
Strattera - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,938 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atomoxetine, Strattera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,417 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more